Chronic Lymphocytic Leukemia - 27 Nov 2020

Part 1 - Welcome and Introduction - Dr. Shweta Surve, AstraZeneca
Part 2 - Introduction to the meeting - Dr. M B Agarwal, Mumbai
Part 3 - Management of RR CLL in the Indian context -current practices - Dr Biswajit D, Puducherry
Part 4 - Management of frail RR CLL - How do I manage? - Dr. Mallikarjun Kalashetty, Bengaluru
Part 5 - Challenges in using 1-G BTKi & chemoimmunotherapy in treatment of RR CLL - Dr. Abha Bhave
Part 6 - Optimal selection of 2G BTKi for treating RR CLL - Dr.Sarit Assouline, Canada
Part 7 - Panel discussion : Management of RR CLL - Dr. M B Agarwal, Mumbai
Part 8 - Vote of thanks - Dr. Shweta Surve , AstraZeneca